What was the acquisition price and timeline for Tubulis, and who acquired it?

Gilead Sciences announced its intent to acquire Tubulis for $3.15 billion in April, and the deal was finalized on May 21.

What core technology did Tubulis commercialize, and where did it originate?

Tubulis commercialized antibody-drug conjugates (ADCs) built with a labeling technology developed in Christian Hackenberger’s lab at the Leibniz Research Institute for Molecular Pharmacology (FMP) and Humboldt University of Berlin.

From Academic Start-Up to Multibillion-Dollar Acquisition

Jun 3, 2026

Gilead Sciences completed a $3.15 billion acquisition of Tubulis, an academic start-up co-founded by Prof. Christian Hackenberger, to commercialize its antibody-drug conjugate technology.

cen

2026-05-05

Use of Gilead's HIV Prevention Shot Rises, But US Insurance Gaps Remain

2026-06-03

From Academic Start-Up to Multibillion-Dollar Acquisition

From Academic Start-Up to Multibillion-Dollar Acquisition

FAQ